Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalVinay Prasad, Sham Mailankody|JAMA Internal Medicine|2017Cited by 497
The high price of anticancer drugs: origins, implications, barriers, solutionsVinay Prasad, Sham Mailankody, Kevin De Jesús|Nature Reviews Clinical Oncology|2017Cited by 430
Evolution of the Randomized Clinical Trial in the Era of Precision OncologyJoseph C. Del Paggio, Christopher M. Booth, Elizabeth A. Eisenhauer et al.|JAMA Oncology|2021Cited by 200
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid CancersVinay Prasad, Sham Mailankody, Victoria Kaestner|JAMA Oncology|2017Cited by 144